Based on the sequences published by the National Center for Biotechnology Information (NCBI), we designed primers to amplify known HIF1α isoforms and determined their presence in benign prostate hyperplasia and prostate cancer with and without NE differentiation. This evidence concerns the gene HIF1A and prostate cancer.